PURPOSE: An intense vascularization of primary tumor mass is associated with a fatal outcome in various types of invasive solid tumors. Interleukin 17 (IL-17), a CD4+ T-cell-derived cytokine, stimulates some tumor cells to secrete angiogenic factors, among which venous endothelial growth factor (VEGF). We assessed whether the expression of IL-17 receptor (IL-17R) represents a marker for the metastasizing ability of osteosarcoma (OS), a very malignant bone tumor. METHODS: We immunoassayed the amount of VEGF secreted by three OS cell lines expressing IL-17R in differing amounts: HOS, MG63 and U-2 OS, and their sensitivity to IL-17 stimulation to secrete VEGF. RESULTS: U-2 OS, which best expresses IL-17R, secreted the highest amounts of VEGF and was the most sensitive to IL-17, whereas MG63 expressed the lowest level of IL-17R, secreted the lowest amount of VEGF and was not sensitive to IL-17. IL-17R expression correlated with VEGF secretion and IL-17 sensitivity. U-2 OS expressed the most dedifferentiated phenotype, which is associated with tumor malignancy. CONCLUSIONS: These results suggest that IL-17R in OS might represent a marker of tumor metastasis potential.
PURPOSE: An intense vascularization of primary tumor mass is associated with a fatal outcome in various types of invasive solid tumors. Interleukin 17 (IL-17), a CD4+ T-cell-derived cytokine, stimulates some tumor cells to secrete angiogenic factors, among which venous endothelial growth factor (VEGF). We assessed whether the expression of IL-17 receptor (IL-17R) represents a marker for the metastasizing ability of osteosarcoma (OS), a very malignant bone tumor. METHODS: We immunoassayed the amount of VEGF secreted by three OS cell lines expressing IL-17R in differing amounts: HOS, MG63 and U-2 OS, and their sensitivity to IL-17 stimulation to secrete VEGF. RESULTS: U-2 OS, which best expresses IL-17R, secreted the highest amounts of VEGF and was the most sensitive to IL-17, whereas MG63 expressed the lowest level of IL-17R, secreted the lowest amount of VEGF and was not sensitive to IL-17. IL-17R expression correlated with VEGF secretion and IL-17 sensitivity. U-2 OS expressed the most dedifferentiated phenotype, which is associated with tumor malignancy. CONCLUSIONS: These results suggest that IL-17R in OS might represent a marker of tumor metastasis potential.
Authors: K Scotlandi; M Serra; M Manara; P Nanni; G Nicoletti; L Landuzzi; D Maurici; N Baldini Journal: Int J Oncol Date: 1993-11 Impact factor: 5.650
Authors: Michael G Alexandrakis; Constantina A Pappa; Spiros Miyakis; Aikaterini Sfiridaki; Maria Kafousi; Athanassios Alegakis; Efstathios N Stathopoulos Journal: Eur J Intern Med Date: 2006-10 Impact factor: 4.487
Authors: M Kaya; T Wada; T Akatsuka; S Kawaguchi; S Nagoya; M Shindoh; F Higashino; F Mezawa; F Okada; S Ishii Journal: Clin Cancer Res Date: 2000-02 Impact factor: 12.531
Authors: Judith A Schwartzbaum; Kun Huang; Sean Lawler; Bo Ding; Jianhua Yu; E Antonio Chiocca Journal: Neuro Oncol Date: 2009-12-24 Impact factor: 12.300
Authors: Michał Jarocki; Julia Karska; Szymon Kowalski; Paweł Kiełb; Łukasz Nowak; Wojciech Krajewski; Jolanta Saczko; Julita Kulbacka; Tomasz Szydełko; Bartosz Małkiewicz Journal: J Clin Med Date: 2022-08-24 Impact factor: 4.964
Authors: Judson Welber Veríssimo de Azevedo; Thales Allyrio Araújo de Medeiros Fernandes; José Veríssimo Fernandes; Jenner Chrystian Veríssimo de Azevedo; Daniel Carlos Ferreira Lanza; Christiane Medeiros Bezerra; Vânia Sousa Andrade; Josélio Maria Galvão de Araújo; José Veríssimo Fernandes Journal: Oncol Lett Date: 2019-12-18 Impact factor: 2.967